Advanced search
Publication Cover
Leukemia & Lymphoma Volume 61, 2020 - Issue 10
Submit an article Journal homepage
608
Views
18
CrossRef citations to date
0
Altmetric
Letters to the Editor

Incidence and characterization of fungal infections in chronic lymphocytic leukemia patients receiving ibrutinib

Michael FreiDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;
,
Samuel L. AitkenDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; ;Center for Antimicrobial Resistance and Microbial Genomics (CARMiG); UTHealth McGovern Medical School, Houston, TX, USA;
,
Nitin JainDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;
,
Philip ThompsonDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;
,
William WierdaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA;
,
Dimitrios P. KontoyiannisDepartment of Infectious Diseases, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
&
Adam J. DiPippoDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-5986-0190
ORCID Icon show all
Pages 2488-2491 | Received 24 Apr 2020, Accepted 17 May 2020, Published online: 12 Jun 2020
 
Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days
Click to increase image sizeClick to decrease image sizeFree first page

Disclosure statement

NJ: Research funding to institution from Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Verastem, Adaptive Biotechnologies, and Precision Biosciences for clinical studies in which NJ is a principal investigator, advisory board member and honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Verastem, Adaptive Biotechnologies, Servier, and Precision Biosciences; PT: Research funding to institution from Pharmacyclics, AbbVie, Genentech and AstraZeneca, advisory board member and honoraria from Pharmacyclics, AbbVie, Gilead, Genentech, speaking fees from Janssen; MF, SLA, WW, DPK, AJD: no relevant disclosures.

Log in via your institution

Access through your institution

Log in to Taylor & Francis Online

Restore content access

Restore content access for purchases made as guest
Purchase options * Save for later

PDF download + Online access

  • 48 hours access to article PDF & online version
  • Article PDF can be downloaded
  • Article PDF can be printed
USD 65.00 Add to cart

Issue Purchase

  • 30 days online access to complete issue
  • Article PDFs can be downloaded
  • Article PDFs can be printed
USD 1,065.00 Add to cart

* Local tax will be added as applicable

Related Research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.